Trial Profile

A 3-day proof-of-concept study assessing multiple doses of IDX 719 in treatment-naive patients with genotype 1, 2, 3 or 4 hepatitis C virus infections.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2013 Data will be presented during Asian Pacific Association for the Study of the Liver (APASL) Liver Week 2013, according to an Idenix Pharmaceuticals media release.
24 Apr 2013 Data was presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL-2013; Abstract No. 1209), according to an Idenix Pharmaceuticals media release.
09 Apr 2013 Data from this trial will be presented at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL) according to an Idenix media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com